DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Eagle Health Investments LP

Eagle Health Investments LP lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 39.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 274,551 shares of the medical device company’s stock after selling 176,941 shares during the quarter. DexCom makes up about 5.2% of Eagle Health Investments LP’s holdings, making the stock its 9th biggest position. Eagle Health Investments LP owned 0.07% of DexCom worth $21,352,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Cerity Partners LLC lifted its position in DexCom by 190.0% in the third quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company’s stock valued at $4,026,000 after acquiring an additional 39,344 shares during the last quarter. Swedbank AB lifted its holdings in shares of DexCom by 15.2% in the 3rd quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock valued at $14,337,000 after purchasing an additional 28,289 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of DexCom by 0.6% in the 3rd quarter. Daiwa Securities Group Inc. now owns 77,099 shares of the medical device company’s stock valued at $5,169,000 after purchasing an additional 490 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of DexCom in the 3rd quarter valued at about $961,000. Finally, D.A. Davidson & CO. grew its stake in DexCom by 22.4% during the 3rd quarter. D.A. Davidson & CO. now owns 32,578 shares of the medical device company’s stock worth $2,184,000 after buying an additional 5,969 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on DXCM shares. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group lifted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $99.82.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last 90 days. 0.30% of the stock is currently owned by insiders.

DexCom Trading Down 1.9 %

Shares of DXCM opened at $72.13 on Thursday. The firm’s 50-day moving average is $82.96 and its two-hundred day moving average is $77.07. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $141.99. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $28.19 billion, a P/E ratio of 50.44, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.